301 related articles for article (PubMed ID: 33461746)
1. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation.
Clarke CGD; Albazaz R; Smith CR; Rowe I; Treanor D; Wyatt JI; Sheridan MB; Guthrie JA
Clin Radiol; 2021 May; 76(5):333-341. PubMed ID: 33461746
[TBL] [Abstract][Full Text] [Related]
2. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
[TBL] [Abstract][Full Text] [Related]
4. Comparison of guidelines for diagnosis of hepatocellular carcinoma using gadoxetic acid-enhanced MRI in transplantation candidates.
Jeon SK; Lee JM; Joo I; Yoo J; Park JY
Eur Radiol; 2020 Sep; 30(9):4762-4771. PubMed ID: 32333148
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of current guidelines for hepatocellular carcinoma diagnosis on gadoxetic acid-enhanced MRI in at-risk patients.
Park SH; Shim YS; Kim B; Kim SY; Kim YS; Huh J; Park JH; Kim KW; Lee SS
Eur Radiol; 2021 Jul; 31(7):4751-4763. PubMed ID: 33389037
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI.
Kim YY; An C; Kim S; Kim MJ
Eur Radiol; 2018 May; 28(5):2038-2046. PubMed ID: 29230525
[TBL] [Abstract][Full Text] [Related]
7. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules.
Terzi E; Iavarone M; Pompili M; Veronese L; Cabibbo G; Fraquelli M; Riccardi L; De Bonis L; Sangiovanni A; Leoni S; Zocco MA; Rossi S; Alessi N; Wilson SR; Piscaglia F;
J Hepatol; 2018 Mar; 68(3):485-492. PubMed ID: 29133247
[TBL] [Abstract][Full Text] [Related]
8. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
9. Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
Delagnes A; Roux M; Vilgrain V; Guiu B; Laurent V; Sutter O; Bricault I; Trillaud H; Aubé C; Paisant A
Eur Radiol; 2024 Apr; 34(4):2283-2293. PubMed ID: 37816923
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
Kierans AS; Song C; Gavlin A; Roudenko A; Lu L; Askin G; Hecht EM
AJR Am J Roentgenol; 2020 Nov; 215(5):1085-1092. PubMed ID: 32877248
[No Abstract] [Full Text] [Related]
11. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.
Lee SE; An C; Hwang SH; Choi JY; Han K; Kim MJ
Eur Radiol; 2018 Apr; 28(4):1551-1559. PubMed ID: 29134355
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy of CEUS LI-RADS for the Characterization of Liver Nodules 20 mm or Smaller in Patients at Risk for Hepatocellular Carcinoma.
Huang JY; Li JW; Lu Q; Luo Y; Lin L; Shi YJ; Li T; Liu JB; Lyshchik A
Radiology; 2020 Feb; 294(2):329-339. PubMed ID: 31793849
[TBL] [Abstract][Full Text] [Related]
13. Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation.
Jhaveri KS; Babaei Jandaghi A; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G
Cancer Imaging; 2023 Feb; 23(1):22. PubMed ID: 36841796
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the current guidelines for diagnosing hepatocellular carcinoma using gadoxetic acid-enhanced magnetic resonance imaging.
Hwang SH; Park MS; Park S; Lim JS; Kim SU; Park YN
Eur Radiol; 2021 Jul; 31(7):4492-4503. PubMed ID: 33409787
[TBL] [Abstract][Full Text] [Related]
15. Optimal lexicon of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of hepatocellular carcinoma modified from LI-RADS.
Hwang SH; Park S; Han K; Choi JY; Park YN; Park MS
Abdom Radiol (NY); 2019 Sep; 44(9):3078-3088. PubMed ID: 31165907
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the diagnostic performance of imaging criteria for HCCs ≤ 3.0 cm on gadoxetate disodium-enhanced MRI.
Byun J; Choi SH; Byun JH; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
Hepatol Int; 2020 Jul; 14(4):534-543. PubMed ID: 32314171
[TBL] [Abstract][Full Text] [Related]
17. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC.
Min JH; Kim JM; Kim YK; Kim H; Cha DI; Kang TW; Choi GS; Choi SY; Ahn S
Liver Int; 2021 Dec; 41(12):2986-2996. PubMed ID: 34242468
[TBL] [Abstract][Full Text] [Related]
18. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma.
Chen N; Motosugi U; Morisaka H; Ichikawa S; Sano K; Ichikawa T; Matsuda M; Fujii H; Onishi H
Magn Reson Med Sci; 2016; 15(1):49-59. PubMed ID: 26104079
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic efficacy of contrast-enhanced ultrasound versus MRI Liver Imaging Reporting and Data System (LI-RADS) for categorising hepatic observations in patients at risk of hepatocellular carcinoma.
Li S; Zhou L; Chen R; Chen Y; Niu Z; Qian L; Fang Y; Xu L; Xu H; Zhang L
Clin Radiol; 2021 Feb; 76(2):161.e1-161.e10. PubMed ID: 33198943
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and clinical significance of discordant LI-RADS
Yokoo T; Singal AG; Diaz de Leon A; Ananthakrishnan L; Fetzer DT; Pedrosa I; Khatri G
Abdom Radiol (NY); 2020 Jan; 45(1):177-187. PubMed ID: 31342103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
